Safety assessment of ripretinib: a real-world adverse event analysis from the food and drug administration adverse event reporting system
The findings of this study align with established drug guidance and uncover new adverse event signals for ripretinib, thereby enhancing clinical monitoring and facilitating risk identification.
Authors
- Jiwei Cao (ORCID: https://orcid.org/0000-0002-3029-8819)
- Shijia Wang (ORCID: https://orcid.org/0000-0001-5063-6224)
- Jianfeng Chen (ORCID: https://orcid.org/0009-0009-1190-1027)
- Yuying Zhou (ORCID: https://orcid.org/0009-0000-7592-4871)
- H. Chen (ORCID: https://orcid.org/0009-0001-2065-8040)
Institutions
- Suzhou Municipal Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-03-31
- DOI
- https://doi.org/10.3389/fonc.2025.1542315
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05